Lifecore Biomedical Inc. - Asset Resilience Ratio
Lifecore Biomedical Inc. (LFCR) has an Asset Resilience Ratio of 0.03% as of February 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore total assets of Lifecore Biomedical Inc. for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2013)
This chart shows how Lifecore Biomedical Inc.'s Asset Resilience Ratio has changed over time. See Lifecore Biomedical Inc. balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Lifecore Biomedical Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Lifecore Biomedical Inc. worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $86.00K | 0.03% |
| Total Liquid Assets | $86.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Lifecore Biomedical Inc. maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lifecore Biomedical Inc. Industry Peers by Asset Resilience Ratio
Compare Lifecore Biomedical Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424 |
Drug Manufacturers - Specialty & Generic | 2.09% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
Annual Asset Resilience Ratio for Lifecore Biomedical Inc. (2005–2013)
The table below shows the annual Asset Resilience Ratio data for Lifecore Biomedical Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2013-05-31 | 0.53% | $1.54 Million | $290.94 Million | -13.10pp |
| 2011-05-31 | 13.63% | $28.12 Million | $206.31 Million | +3.43pp |
| 2010-05-31 | 10.20% | $20.42 Million | $200.20 Million | -4.52pp |
| 2009-05-31 | 14.72% | $22.50 Million | $152.87 Million | +4.99pp |
| 2008-05-31 | 9.72% | $14.64 Million | $150.59 Million | +7.76pp |
| 2005-05-31 | 1.97% | $1.97 Million | $100.08 Million | -- |
About Lifecore Biomedical Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device … Read more